Abstract
The promise of efficacious vaccines against SARS-CoV-2 is fulfilled and vaccination campaigns are starting worldwide. However, the fight against the pandemic is far from over. Here, we propose an age-structured compartmental model to study the interplay of disease transmission, vaccines rollout, and behavioural dynamics. We investigate, via in-silico simulations, individual and societal behavioural changes, possibly induced by the start of the vaccination campaigns, and manifested as a relaxation of non-pharmaceutical interventions. We calibrate the model using real epidemiological data for three different countries: Italy, France, and the United Kingdom. We explore different vaccination rollout speeds, prioritization strategies, and vaccine efficacy as well as multiple behavioural responses. Our findings suggest that early relaxation of safe behaviours can jeopardize the benefits brought by the vaccine in the short term: a fast vaccine distribution and policies aimed at keeping high compliance of individual safe behaviours are key to mitigate disease resurgence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N.G. acknowledges support from the Doctoral Training Alliance. P.B. acknowledges support from Intesa Sanpaolo Innovation Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data and code used in this paper are publicly available at https://github.com/ngozzi/vaccine-behaviour
Data Availability
The data is available upon request
